Publications
Included here is a list of publications from OCG programs. All published data are available to the research community through the program-specific data matrices.
* denotes publications from the CTD2 initiative that are results of intra-Network collaborations
Review on using patient-derived three-dimensional “organoid” models as a personal cancer model to develop effective treatment options.
CTD2 review focused on signaling pathways mediated by the epidermal growth factor receptor (EGFR) and mutant EGFRvIII and novel therapies to overcome treatment resistance in glioblastoma.
A study of nearly 1,000 pediatric acute myeloid leukemia (AML) cases revealed marked differences between the genomic landscapes of pediatric and adult AML and offered directions for future work.
Loss-of-function CRISPR/Cas9-based cancer dependency screes in MYCN-amplified neuroblastoma identified polycomb repressive complex 2 as a druggable pathway.
CTD2 UCSF-2 review on the importance of 4EBP1 as a biomarker for the efficacy of PI3K-AKT-mTOR inhibitors in glioblastoma.
Molecular assessment of participants from pediatric AML trials showed that recurrent structural alterations and age-specific mutational profiles can be used to stratify subjects in terms of overall and progression-free survival, and it highlighted the need for age-tailored targeted therapies.
Researchers identified that MAPK-interacting kinase 1 (MNK1) is overexpressed in the mesenchymal (MES) phenotype of glioblastoma, which may cause therapeutic resistance to arsenic trioxide (ATO). This study supports the use of the MNK inhibitor along with ATO to treat MES glioblastoma patients.
Researchers identified abundant expression of miR-106a, a marker for treatment resistance, in relapsed and refractory pediatric AML through a comprehensive miRNA profile to identify potential biomarkers as predictors for improved outcomes.